SenzaGen: Invitation to 2021 Year-end Report conference call on Feb 11 at 9.30 CET

SenzaGen is pleased to invite press and investors to a conference call on Friday February 11 at 9.30 CET where President and CEO Peter Nählstedt comments SenzaGen’s 2021 second half year and full year results. The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session.

Phone number for the conference
To participate in the conference call, use the dial-in numbers below.

FR: +33170750736
DE: +4969222239166
SE: +46850558352
CH: +41225675632
NE: +31107129163
UK: +443333009031

Weblink
https://tv.streamfabriken.com/senzagen-q4-2021

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen aims to be a leader in non-animal toxicology testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® test platform, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s Certified Adviser. 

Attachments

SenzaGen: Invitation to 2021 Year-end Report conference call on Feb 11 at 9.30 CET